Michaela Mattheus — ASN Events
ads-adea-2016.m.asnevents.com.au
Schedule · Michaela Mattheus. , ,. Presentations this author is a contributor to: Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: ...
Lectura de un artículo: "Empagliflozina - EMPA-REG OUTCOME - realidad…
es.slideshare.net
Más información en nuestra web: www.csjesusmarin.es Nuestro residente R1 Francisco Campillo Palma nos trae la lectura de un artículo de reciente aparición sobr…
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes...
www.scienceopen.com
Authors: Christoph Wanner , John M. Lachin , Silvio E. Inzucchi , David Fitchett , Michaela Mattheus , Jyothis George , Hans J. Woerle , Uli C. Broedl , Maximilian ...
Lack of drug-drug interaction between empagliflozin, a sodium glucose...
www.scienceopen.com
inhibitor, and warfarin in healthy volunteers. Authors: E Macha, Michaela Mattheus, S Pinnetti, H-J Woerle, Peter Rose. Publication date:
The effect of empagliflozin on muscle sympathetic nerve activity in...
www.sciencedirect.com
... Christoph Wanner, MD, Martina Heer, PhD, Sreeraj Macha, PhD, Michaela Mattheus, Dipl Biomath, Søren S. Lund, MD, Hans J. Woerle, MD, Uli C. Broedl, MD.
Michaela Mattheus – ScienceOpen
www.scienceopen.com
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Authors: ...
Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2...
link.springer.com
Sitagliptin in Healthy Volunteers. Tobias Brand ∙ Sreeraj Macha ∙ Michaela Mattheus ∙ Sabine Pinnetti ∙ Hans J. Woerle. To view enhanced ...
Alle Infos zum Namen "Michaela Mattheus"
Michaela Mattheus
www.infona.pl
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers · Sreeraj Macha, Michaela Mattheus, Sabine ...
"Empagliflozin and Cerebrovascular Events in Patients With Type 2...
hsrc.himmelfarb.gwu.edu
By Bernard Zinman, Silvio E Inzucchi, John M Lachin, et al., Published on
Cardiovascular Benefit of Empagliflozin Across the Spectrum of ...www.diabetescenters.org › bibcite › reference
www.diabetescenters.org
Author, Silvio E Inzucchi, Kamlesh Khunti, David H Fitchett, Christoph Wanner, Michaela Mattheus, Jyothis T George, Anne Pernille Ofstad, Bernard Zinman.
After the first administration, empagliflozin improved the recovery...
docplayer.net
... HbA1c and change in HbA1c: results from EMPA-REG OUTCOME Silvio E. Inzucchi, David Fitchett, Christoph Wanner, Michaela Mattheus, Jyothis T. George, ...
Consistent effects of empagliflozin on cardiovascular and PubMedpubmed.ncbi.nlm.nih.gov › ...
pubmed.ncbi.nlm.nih.gov
Christoph Wanner , Silvio E Inzucchi , Bernard Zinman , Audrey Koitka-Weber , Michaela Mattheus , Jyothis T George , Maximilian von Eynatten , Sibylle J ...
Effect of Empagliflozin on the Steady-State Pharmacokinetics of ...www.infona.pl › resource
www.infona.pl
Sreeraj Macha, Michaela Mattheus, Sabine Pinnetti, Hans J. Woerle, Uli C. Broedl · Details · Contributors · Fields of science · Bibliography · Quotations ...
Effects of empagliflozin on first and recurrent clinical events in...
utsouthwestern.pure.elsevier.com
... Jyothis T. George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S. Lund.
Altmetric – Cardiovascular Mortality Reduction With Empagliflozin in...
jacc.altmetric.com
David Fitchett, Silvio E. Inzucchi, John M. Lachin, Christoph Wanner, Philippe van de Borne, Michaela Mattheus, Odd Erik Johansen, Hans J.
Empagliflozin and Kidney Function Decline in Patients with Type research.rug.nl › publications › empagliflozin-and-k...
research.rug.nl
... Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Stefan Hantel, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten, Per-Henrik Groop.
Effects of empagliflozin on the urinary albumin-to-creatinine ...read.qxmd.com › read › effects-of-...
read.qxmd.com
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes ...
Empagliflozin and Cardiovascular Outcomes in Altmetricwww.altmetric.com › details
www.altmetric.com
Kohei Kaku, Jisoo Lee, Michaela Mattheus, Stefan Kaspers, Jyothis George, Hans-Juergen Woerle. Abstract. In the EMPA-REG OUTCOME(®)trial, empagliflozin ...
Empagliflozin and Cardiovascular Outcomes in Patients With ...my.americanheart.org › documents
my.americanheart.org
Silvio E Inzucchi, Christoph Wanner, John M Lachin, David Fitchett,. Stefan Hantel, Michaela Mattheus,. Theresa Devins, Odd Erik Johansen, Hans J Woerle,.
Empagliflozin and Cardiovascular Outcomes in Patients with ...
my.americanheart.org
KG, Biberach, Germany; Michaela Mattheus, Boehringer Ingelheim Pharma GmbH & Co. KG,. Ingelheim, Germany; Theresa Devins, Boehringer Ingelheim ...
Improved cardiovascular outcomes with empagliflozin treatment |...
www.cardio-debate.com
... Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl.
Empagliflozin and Kidney Function Decline in Patients with Type 2...
researchportal.helsinki.fi
... and Michaela Mattheus and Stefan Hantel and Hans-Juergen Woerle and Broedl, {Uli C.} and {von Eynatten}, Maximilian and Per-Henrik Groop",.
Empagliflozin and progression of kidney disease in type 2 diabetes...
research.sahmri.org.au
... Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian Von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans ...
Cardiovascular (CV) Benefit of Empagliflozin Across the Spectrum of ...www.physiciansweekly.com › cardiovascular-cv-be...
www.physiciansweekly.com
· By Silvio E Inzucchi,Kamlesh Khunti,David H Fitchett,Christoph Wanner,Michaela Mattheus,Jyothis T George,Anne Pernille Ofstad,Bernard Zinman
sortiert nach Relevanz / Datum